ESTC vs XTLB vs MDB Stock Comparison

Elastic, Xtl Biopharmaceuticals and MongoDB Prices as of Oct 27, 2026 Peers: Industry group
ESTC Elastic N.V.
$105.51 +19.9% 1M +19.0% 1Y
Market cap
$11.09B
P/E
29.4x
Revenue (TTM)
$1.80B
Div. yield
–
Data Infrastructure Technology
5 wins
MDB MongoDB, Inc.
$389.84 -5.0% 1M +14.6% 1Y
Market cap
$31.40B
P/E
532.8x
Revenue (TTM)
$2.78B
Div. yield
–
Data Infrastructure Technology
4 wins

Head to Head

9 decided of 12

Elastic leads on 5 of the 12 questions below (Elastic 5, MongoDB 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionESTCXTLBMDBLeader
Larger companyMarket capitalisation $11.09B $17.13M $31.40B MDB
Cheaper on earningsLower P/E, profitable companies only 29.4x -2.3x 532.8x ESTC
Cheaper on forward earningsLower price / next fiscal year consensus EPS 30.1x — 55.7x ESTC
Faster revenue growthRevenue growth, trailing twelve months +16.2% — +25.5% MDB
More profitableNet margin, trailing twelve months 20.8% — 2.1% ESTC
Better return on capitalReturn on invested capital 0.0% — — –
Less leveragedLower net debt / EBITDA -10.8x — — –
Higher dividend yieldTrailing dividend yield — — — –
Better 1-year returnPrice return, last 12 months +19.0% -62.3% +14.6% ESTC
Better 5-year returnAnnualised price return, 5 years -9.3%/yr -34.7%/yr -5.0%/yr MDB
Less volatileAnnualised volatility, 1 year 58.1% 108.7% 72.7% ESTC
Higher overall scoreMean of the five percentile scores vs peers 71/100 — 73/100 MDB

Percentile Scorecard

ESTCXTLBMDB

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisESTCXTLBMDB
Valuation 70 #38 of 124 24 #476 of 625 46 #68 of 124
Growth 81 #22 of 113 – 98 #3 of 113
Profitability 67 #37 of 109 – 71 #32 of 109
Financial Health 52 #61 of 127 2 #642 of 656 80 #26 of 127
Shareholder Returns 86 #10 of 65 – 69 #21 of 65
Overall 71 – 73
  • ESTC ranked among 137 companies in Infrastructure Software
  • XTLB ranked among 672 companies in Pharmaceuticals and Biotechnology
  • MDB ranked among 137 companies in Infrastructure Software

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodESTCXTLBMDBSPY
1 month +19.9%-19.6%-5.0% -0.2%
3 months +70.0%-39.1%+25.5% +3.9%
6 months +122.4%-21.3%+51.0% +8.2%
Year to date +39.9%-22.0%-7.1% +12.9%
1 year +19.0%-62.3%+14.6% +12.3%
3 years +39.7%-44.8%+16.3% +87.4%
3 years, per year +11.8%-18.0%+5.2% +23.3%
5 years -38.5%-88.1%-22.7% +67.9%
5 years, per year -9.3%-34.7%-5.0% +10.9%
10 years —-89.6%— +261.1%
10 years, per year —-20.3%— +13.7%

Risk

MeasureESTCXTLBMDBSPY
Volatility, 1Y 58.1%108.7%72.7% 12.7%
Downside volatility, 1Y 59.1%90.3%76.7% 12.7%
Beta vs S&P 500, 1Y 1.140.541.90 1.00
Return / volatility, 1Y 0.33-0.570.20 0.97
Max drawdown, 5Y -76.8%-88.9%-76.5% -25.4%
From 52-week high -0.7%-62.3%-17.5% -1.2%
52-week high $106.26$4.80$472.29 $779.14
52-week low $43.30$1.78$225.95 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleESTCXTLBMDB
P/E now vs peer median 29.4xmedian 38.6x -2.3xmedian 17.2x 532.8xmedian 38.6x
P/S now vs peer median 6.2xmedian 4.4x 2,447xmedian 9.0x 11.3xmedian 4.4x
EV/EBITDA now vs peer median 123.3xmedian 34.5x —median 16.3x 2,347xmedian 34.5x
P/FCF now vs peer median 31.8xmedian 29.4x -16.7xmedian 18.7x 47.7xmedian 29.4x
P/B now vs peer median 8.6xmedian 3.3x -67.4xmedian 2.2x 10.5xmedian 3.3x
PEG now vs peer median 0.55median 1.28 —median 0.33 17.67median 1.28

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsESTCXTLBMDB
Revenue $1.80B – $2.78B
Gross profit $1.36B – $2.02B
Operating income -$47.61M – -$14.52M
Net income $375.64M – $58.90M
Free cash flow $349.04M – $659.02M
R&D $455.30M – $780.02M
EPS (diluted) $3.59 – $0.72
Cash & equivalents $879.87M $76.00K $1.00B
Total debt $571.20M $530.00K –
Shares (diluted) 104.64M 8.96M 82.00M
Enterprise value $5.62B $13.93M $21.87B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricESTCXTLBMDB
P/E 29.4x -2.3x 532.8x
P/FCF 31.8x -16.7x 47.7x
P/Operating cash flow 31.3x – 47.1x
P/S 6.2x 2,447x 11.3x
P/B 8.6x -67.4x 10.5x
P/Tangible book 8.6x -67.4x 10.6x
EV/EBITDA 123.3x – 2,347x
EV/EBIT -214.3x – -1,996x
EV/Revenue 5.7x – 10.4x
EV/FCF 29.2x – 44.0x
EV/Operating cash flow 28.8x – 43.5x
PEG (3Y EPS CAGR) 0.55 – 17.67

Growth

14 metrics
MetricESTCXTLBMDB
Revenue growth (1Y) 16.2% – 25.5%
Revenue CAGR (3Y) 17.4% – 23.2%
Gross profit growth (1Y) 16.7% – 26.1%
Gross profit CAGR (3Y) 18.8% – 22.5%
Operating income growth (1Y) -56.0% – 91.2%
Operating income CAGR (3Y) 37.5% – 62.4%
Net income growth (1Y) 549.9% – 174.9%
Net income CAGR (3Y) 55.3% – 30.9%
EPS growth (1Y) 555.6% – 174.1%
EPS CAGR (3Y) 53.7% – 30.1%
Operating cash flow growth (1Y) 11.3% – 146.9%
Operating cash flow CAGR (3Y) 62.1% – 139.5%
Free cash flow growth (1Y) 11.2% – 174.7%
Free cash flow CAGR (3Y) 63.2% – 144.3%

Profitability

14 metrics
MetricESTCXTLBMDB
Gross margin 75.5% – 72.7%
EBITDA margin 4.6% – 0.4%
Operating margin -2.6% – -0.5%
Pretax margin -1.1% – 2.7%
Net margin 20.8% – 2.1%
FCF margin 19.4% – 23.7%
Operating cash flow margin 19.6% – 24.0%
Return on equity 29.2% – 2.0%
Return on assets 12.2% – 1.6%
Return on invested capital 0.0% – –
Return on capital employed -2.3% – -0.5%
Asset turnover 0.6x – 0.7x
Cash conversion (OCF / net income) 0.9x – 11.3x
Stock comp / revenue 16.8% – 20.3%

Financial Health

11 metrics
MetricESTCXTLBMDB
Debt / assets 19.0% 83.1% –
Debt / equity 0.4x -0.5x –
Net debt / EBITDA -10.8x – –
Debt / FCF 1.6x – –
Liabilities / assets 56.8% 253.0% 21.1%
Equity / assets 43.2% -153.0% 78.9%
Interest coverage -1.9x – -6.1x
Current ratio 1.8x 0.4x 4.9x
Quick ratio 1.6x 0.4x 4.5x
Cash ratio 1.4x 0.2x 3.8x
Altman Z-score 4.44 – 24.44

Shareholder Returns

7 metrics
MetricESTCXTLBMDB
Dividend yield – – –
Net buyback yield 3.1% – 1.2%
Shareholder yield 3.1% – 1.2%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusESTCXTLBMDB
Forward P/E 30.1xFY2026 – 55.7xFY2026
EPS, next fiscal year $3.51FY2026 – $7.00FY2026
EPS growth, next FY +36.6%FY2026 – +40.8%FY2026
EPS growth, the year after +19.4% – +6.4%
Revenue, next fiscal year $1.88BFY2026 – $2.89BFY2026
Revenue growth, next FY +8.2%FY2026 – +17.5%FY2026
Revenue growth, the year after +18.3% – +33.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersESTCXTLBMDB
Held by institutions 86.4% – 92.6%
Institutions holding 371 – 870
Change in shares held, QoQ +1.7% – +4.3%
Institutions buying 199 – 493
Institutions selling 129 – 278
Buyers to sellers 1.54 – 1.77

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ESTCXTLBMDB
ESTC 1.00 0.00 0.56
XTLB 0.00 1.00 -0.10
MDB 0.56 -0.10 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ESTC, XTLB and MDB?

MongoDB (MDB) is the largest by market capitalisation: Elastic (ESTC) $11.09B, Xtl Biopharmaceuticals (XTLB) $17.13M, MongoDB (MDB) $31.40B.

Which stock is cheaper, ESTC, XTLB and MDB?

Elastic (ESTC) trades on the lowest price-to-earnings ratio (Elastic (ESTC) 29.4x, Xtl Biopharmaceuticals (XTLB) -2.3x, MongoDB (MDB) 532.8x). On next year's consensus earnings, Elastic (ESTC) is cheapest (Elastic (ESTC) 30.1x, MongoDB (MDB) 55.7x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

MongoDB (MDB) grew revenue fastest over the trailing twelve months: Elastic (ESTC) +16.2%, MongoDB (MDB) +25.5%.

Which company is more profitable?

Elastic (ESTC) has the highest net margin (Elastic (ESTC) 20.8%, MongoDB (MDB) 2.1%).

Which stock has performed better?

Over the past year Elastic (ESTC) returned the most: Elastic (ESTC) +19.0%, Xtl Biopharmaceuticals (XTLB) -62.3%, MongoDB (MDB) +14.6%. Over five years, MongoDB (MDB) compounded fastest (Elastic (ESTC) -9.3%/yr, Xtl Biopharmaceuticals (XTLB) -34.7%/yr, MongoDB (MDB) -5.0%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Elastic (ESTC) has been the steadiest (Elastic (ESTC) 58.1%, Xtl Biopharmaceuticals (XTLB) 108.7%, MongoDB (MDB) 72.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ESTC, XTLB and MDB?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Elastic (ESTC) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.